TXG
TXG
US88025U1097
10x Genomics, Inc.
Loading chart...

Company Profile

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Latest News

Related stocks

BRKR
BRKR • United States
Bruker Corporation
58.84 USD
8.96B USD 1Y +67.3%
PODD
PODD • United States
Insulet Corporation
135.28 USD
9.38B USD 1Y -57.4%
BIO
BIO • United States
Bio-Rad Laboratories, Inc.
366.16 USD
9.8B USD 1Y +19%
TMDX
TMDX • United States
TransMedics Group, Inc.
77.87 USD
2.69B USD 1Y -33.1%
GMED
GMED • United States
Globus Medical, Inc.
74.65 USD
10.02B USD 1Y +21.4%
BFLY
BFLY • United States
Butterfly Network, Inc.
8.25 USD
2.2B USD 1Y +199.6%
NEOG
NEOG • United States
Neogen Corporation
11.85 USD
2.59B USD 1Y +101.2%
ALMR
ALMR • United States
Alamar Biosciences, Inc.
25.27 USD
1.75B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
70.7% p.a.
Max Drawdown (5Y)
-96.1%
Sharpe Ratio (5Y)
-0.22
Beta Factor
1.99
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Unprofitable business model: The company is currently generating net losses.
High market risk: Beta of 1.99 indicates above-average volatility compared to the broader market.
🔴 High valuation risk: Avg P/E of 1051.9 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (70.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -96.1% in the extended horizon.
ende